Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
... in major and minor Thrombolysis in Myocardial infarction
(TIMI)-scale bleeding when given with current ... predominantly due to a reduction in myocardial infarction
(heart attack), 7 percent with placebo compared ... being conducted by the Thrombolysis in Myocardial infarction
(TIMI) Study Group.
The Phase III Thrombin ...
Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
... when evaluated at 10 days, and
reduction in the infarction
size when evaluated at 60 days. In some of ... the amount of damage from myocardial infarction
by assisting in
the formation of functional ... ACUTE MYOCARDIAL INFARCTION
Acute myocardial infarction
(heart attack), results from the ...
Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
1. Type 1: Spontaneous myocardial infarction
related to ischemia due to
a primary coronary event
Type 2: Myocardial infarction
secondary to ischemia due to either
increased ... blood supply
Type 4/Type 5: Myocardial infarction
associated with PCI/CABG
Thygesen K et al. ...
n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
... 6% (p=0.147) heart failure Myocardial infarction
18% (p=0.121) Stroke ... demonstrated that a subgroup of
patients with left ventricular dysfunction ... whose
cardiovascular benefit in post- myocardial infarction
patients had been
established by the ...
Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
... for the potential
treatment of acute myocardial infarction
(heart attack), has been published
online by ... patients after a heart attack or acute
(MI), the investigators evaluated the effects ... and rapid cooling of patients with myocardial infarction
(MI or heart
attack), which is being co-sponsored ...
BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
... in patients with
ST-elevation myocardial infarction
(STEMI), a serious form of heart attack.
The ... College of Cardiology (ACC).
"Acute myocardial infarction
is a major medical problem, and the
present study ... "For patients with acute ST-elevation myocardial infarction
primary coronary intervention after ...
Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
... events in patients
with recent myocardial infarction
(hear attack), recent ischaemic stroke ... elevation myocardial infarction
which does not show ST elevation in ECG), and acute
are considered to be the series of the ...
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
found similar rates of myocardial infarction
(heart attack) and mortality
between the ... metal stent
(p=0.850), the Q- wave myocardial infarction
rate for each treatment arm
was 1.1 percent (p=1.00) and the non-Q-wave myocardial infarction
were 7.4 percent for the CYPHER(R) Stent ...
InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
... in the iMOS registry was a 54 year old male treated for
acute myocardial infarction
(STEMI) caused by a thrombus occluding the LAD
artery. MGuard(TM) was ... is Dr. Alexandre Abizaid and the
MAGICAL Trial (MGuard in Acute Myocardial infarction
Study) in Poland with
Dr. Dariusz Dudek as Principal Investigator. The ...
New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial
... differences between PCI and CABG in rates of death or myocardial infarction
(heart attack), although PCI patients were more likely to require a repeat ... groups, with a combined rate of all-cause death, stroke and myocardial infarction
(MI) of 7.6 percent for PCI and 7.7 percent for CABG (p=0.98). The rate ...
Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use
... of primary percutaneous coronary intervention (PCI) in Acute Myocardial infarction
(AMI) patients, who accounted for nearly 150,000 PCIs in the US in 2008. ... released positive clinical data, which showed that ST-elevation myocardial infarction
(STEMI) patients who receive aspiration with stenting have better blood ...
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
... TAXUS Liberte Atom Stent, and a significantly reduced rate of myocardial infarction
(heart attack) in patients with long lesions treated with the TAXUS ... Long Stent reported a significantly reduced 12-month rate of myocardial infarction
(1.4% vs. 6.5%, p= 0.0246) as well as a trend toward fewer stent ...
HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
... to bare-metal stenting in
patients experiencing an acute myocardial infarction
referred to as a heart attack. With 3,006 patients ... showed comparable overall safety outcomes (death,
stroke, myocardial infarction
or stent thrombosis) between the two
treatment groups (8.0 percent for the ...
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
... and efficacy outcomes defined as cardiac death, heart attack
or MI) or target vessel revascularization (TVR).
-- A clinically ... outcomes for
patients, defined as cardiac death, heart attack (myocardial infarction
MI), or ischemia-driven target lesion revascularization (TLR driven by ...
Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
... 1.03, 95% CI = 0.79, 1.35), and -- No increased risk for myocardial infarction
(relative risk ratio for myocardial infarction
0.78, 95% CI = 0.59, 1.02) associated with tiotropium.(3) The UPLIFT ...
Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test
... risk for cardiovascular disease and an increased risk for
at a younger age, that is, an early first heart
The IL1B gene ... disease
has a number of forms but the most common are myocardial infarction
angina pectoris which affect the heart itself. There are well ...
Drug-Eluting Stents Outperform Bare Stents in Heart Attack
... with a type of heart
attack known as ST-segment-elevation myocardial infarction
(STEMI). In the
study, drug-eluting stents outperformed bare-metal stents, ... this came without an
extra price to pay in terms of death, myocardial infarction
Dr. Valgimigli will present the results of this ...
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
... Medical School and investigator with the
Thrombolysis in Myocardial infarction
(TIMI) Study Group, at the Society
for Cardiovascular Angiography and ... patients with stent thrombosis, 89 percent either died or had a
associated with the event.
The rate of major bleeding was higher in all ...
Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
... was associated with
a lower incidence rate of subsequent myocardial infarction
compared with NPH insulin. The new findings, presented at the ... hazard models were used to compare the rate of
subsequent myocardial infarction
(MI) events (defined by ICD-9 codes)
following initiation of glargine ...
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
... reduction in cardiovascular events, specifically periprocedural
(MI) in the ACS patients undergoing PCI. About the Thrombin Receptor ... events, including acute coronary syndromes (ACS), such
as myocardial infarction
(MI), and ischemic stroke, which are the leading
causes of death. ...
Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
... or placebo. Primary endpoints of the study were non-fatal
(MI--heart attack), stroke and cardiovascular death.
Results demonstrated ... to be predominantly due to a significant decrease in
non-fatal myocardial infarction
in the Vitamin E group. "Our research group has postulated that the ...
Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
... cardiac death (4.4% vs. 4.5%, p=0.85),
and all death and Q-wave myocardial infarction
(10.9% vs. 12.0%, p=0.57)
were numerically lower in the TAXUS Stent group ... the BMS group.
The five-year rates of cardiac death and Q-wave myocardial infarction
identical between the TAXUS Stent and the control BMS (5.3% vs. ...
Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
... further significant reduction in the incidence of
Non-Q-Wave Myocardial infarction
(MI, or heart attack) occurring at the
time of the procedure compared to ... over the TAXUS Express Stent (100.0%
vs. 96.3%, p=0.0431). Myocardial infarction
(MI) was significantly reduced in TAXUS Liberte
Long Stent patients ...
Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs. Angiographic Guidance of Stent Deployment in Patients with Multivessel Disease
... of major adverse cardiac
events (MACE), including death, myocardial infarction
and repeat coronary
revascularization at one year. Secondary endpoints include global cost
effectiveness after one year, cardiac death and myocardial infarction
at one year, functional class at one year, number of anti-anginal ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... infarction. N Engl J Med 2007; 356: 1723-35.
7 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction
in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. www.thelancet.com published online April 2, 2008, ...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... studies. Lacosamide should be used with caution in patients with known conduction problems or severe cardiac disease such as a history of myocardial infarction
or heart failure. Caution should especially be exerted when treating elderly patients as they may be at an increased risk of cardiac disorders or ...
Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
... rates of device- and/or procedure-related major adverse events (MAE) at nine months. MAE are currently defined as death within 30 days, myocardial infarction
(MI, or heart attack) occurring during related hospitalization, target vessel revascularization (TVR) through nine months and amputation of the ...
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease
... for the two treatment groups, with no overall statistically significant differences between PCI and CABG surgery in rates of death or myocardial infarction
(MI, or heart attack), although there were more strokes in patients treated with CABG surgery. The rate of repeat revascularization was higher in ...
RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
... Consta with caution in patients with conditions and medical conditions that could affect metabolism or hemodynamic responses. (e.g. Recent Myocardial infarction
or unstable cardiac disease)
Extrapyramidal Symptoms (EPS): The overall incidence of EPS-related adverse events in patients treated with 25 mg ...
New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
... those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction
on starting calcium channel blocker therapy or at the time of dosage increase.
Congestive Heart Failure
In general, calcium channel blockers ...
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
... Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients undergoing catheter treatment for an acute myocardial infarction
(AMI), or heart attack.
With more than 3,000 patients enrolled worldwide, HORIZONS AMI is the largest randomized trial to compare the use of ...
Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
... minus 216 days (range: 537 ¿ 1,148, median: 651). There were no reports of device thrombosis, hemolysis, peripheral thromboembolic events, myocardial infarction
or chronic renal dysfunction.
The total major adverse event rates during DuraHeart support were acceptable in comparison to first generation ...
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
... activity in the study participants' blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction
and stroke. The study's authors further concluded that the ability to identify postmenopausal women with an increased risk of arterial thrombosis or ...
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
... favored the PROMUS
(XIENCE V) Stent compared to the TAXUS Stent (6.4% vs. 14.9% respectively,
p=0.029), while the individual components of Myocardial infarction
Ischemia-Driven Target Lesion Revascularization (ID-TLR) were not
significantly different (MI: 3.3% vs. 6.8%, p=0.20; ID-TLR: 4.2% vs. ...
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
... MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction
or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply).
In addition, the SPIRIT II results ...
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
... safety for the two treatment groups, with no overall statistically significant differences between PCI and CABG in rates of death or myocardial infarction
(MI, or heart attack), although there were significantly more strokes in patients treated with CABG. The rate of repeat revascularization was ...
Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
... incidence of mortality at 30 days is the attribute that most influences surveyed cardiologists' prescribing decisions in non-ST elevation myocardial infarction
(NSTEMI). Data and the opinions of interviewed thought leaders indicate that current and emerging drugs, including Eli Lilly/Daiichi Sankyo's Efient, ...
American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
... surveys of Emergency Medical Services (EMS) systems indicate the need for improvements in the way heart attack, specifically ST-elevation myocardial infarction
(STEMI), is managed.
STEMI is the most serious and deadly type of heart attack, characterized by a complete blockage of a coronary artery. It ...
Savient Provides Update on Pegloticase BLA
... that the FDA has widely accepted as a method of evaluating cardiovascular risk. APTC cardiovascular events include deaths, nonfatal myocardial infarction
or nonfatal stroke. Dr. White and his panel concluded that:
As a result of the post-hoc blinded adjudication and unblinded review ...
MGuard(TM) Coronary Stent System Approved in Israel
... underway. The
MAGICAL Trial (MGuard in SVG and Native Coronaries Trial) is being conducted
in Brazil and the GUARD Trial (MGuard in Acute Myocardial infarction
in Poland. The main objective of the MAGICAL trial is to investigate the
safety and efficacy of the MGuard stent in human subjects who are ...